How Biotech Startup Funding Will Change in the Next 10 Years
Life Sciences VCs that incubate and spin-out their own companies put serious muscle behind the startups, in two main areas: money and leadership. The article notes the first, going on to suggest large upfront financing is no longer necessary, but glosses over the second. In biotech it is still very much the status quo to have seasoned execs leading startups. Not because younger founders are incapable, but rather this is what pharma execs want to see, and have connections with. It&#x27;s hard enough for a startup to get pilots and deals with pharmacos, exponentially so if the founders just took CS 270 with the CEO&#x27;s grandkid.